Article

Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.

Unit of Anatomic Pathology, Department of Surgery, Faculty of Medicine, E-14004 Cordoba, Spain.
The American journal of surgical pathology (Impact Factor: 4.59). 01/2010; 34(3):371-6. DOI: 10.1097/PAS.0b013e3181cd385b
Source: PubMed

ABSTRACT In this report, we present the clinicopathologic features of 27 cases of the lipid cell variant of urothelial bladder carcinoma. This is a rare variant of bladder cancer recognized by the current WHO classification of urologic tumors. The lipid cell component varied from 10% to 50% of the tumor specimen; in 11 cases the lipid cell component composed greater than 30% of the tumor. The architectural pattern of the tumor varied from solid expansile to infiltrative nests. The large epithelial tumor cells had an eccentrically placed nucleus and abundant vacuolated cytoplasm resembling signetring lipoblasts. Mucin stains were negative in all the cases. Typical features of high grade conventional urothelial carcinoma were present in all the cases with micropapillary or plasmacytoid carcinoma in 2 and 1 cases, respectively; extensive squamous or glandular differentiation was present in 2 additional cases. Most neoplastic cells had nuclei of intermediate nuclear grade with occasional nuclear pleomorphism. Immunohistochemical staining showed that the lipid cell component was positive for cytokeratins 7, 20, CAM 5.2, high molecular weight (34ssE12) and AE1/AE3, epithelial membrane antigen, and thrombomodulin; vimentin and S100 protein were negative. The loss of heterozygosity (LOH) analysis was done on 8 cases using 4 polymorphic microsatellite markers (D9S171, D9S177, IFNA, and TP 53); LOH at least in 1 marker was present in 6 cases. The LOH results were the same for lipid variant and conventional urothelial carcinoma. Pathologic stage was Ta (n=1), T1 (=2), T2, at least (n=7), T3a (n=4), T3b (n=8), and T4a (n=5). Electron microcopy analysis based on 2 cases supported lipid content in tumor cells. Follow-up information was available in all the cases, ranging from 6 to 58 months (mean, 28 mo). Sixteen of the patients died of disease at 16 to 58 months (mean, 33 mo) and 8 patients were alive with disease at 8 to 25 months (mean, 22 mo). Another 3 patients died of other causes at 6 to 15 months (mean, 10 mo). In summary, lipid cell urothelial bladder carcinoma is typically associated with advanced stage high-grade urothelial carcinoma, in which the prognosis is poor and clonally related to the concurrent conventional urothelial carcinoma. In limited samples, it may be misdiagnosed as liposarcoma, sarcomatoid carcinoma (carcinosarcoma), or signetring cell carcinoma. Morphologic distinction from other malignant neoplasms with lipid cell phenotype is critical for its clinical management.

Download full-text

Full-text

Available from: Antonio Lopez-Beltran, Sep 05, 2015
2 Followers
 · 
170 Views
 · 
61 Downloads
  • Source
    • "Therefore, whichever criteria one may apply for the definition of MPC, it is recommended to report the presence and the proportion of MP component in the pathology report. MPC is frequently accompanied by in situ carcinoma, and coexistence has been reported with adenocarcinoma [11, 12], small cell carcinoma [12], sarcomatoid carcinoma [13], pleomorphic giant cell carcinoma [14], lipoid variant [15], or plasmacytoid variant of UC [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Micropapillary carcinoma (MPC) of urinary tract is an uncommon variant of urothelial carcinoma with significant diagnostic and prognostic implications. Though MPC shows characteristic microscopic features, there exists interobserver variability and also it needs to be differentiated from the metastasis from other organs. The prognosis is generally poor, depending on the proportion of the micropapillary component in some reports. Early cystectomy in cases with only lamina propria invasion may be indicated according to recent studies. This review outlines the general features of this entity and briefly comments on the controversies and the recent development.
    Advances in Urology 10/2011; 2011:217153. DOI:10.1155/2011/217153
  • [Show abstract] [Hide abstract]
    ABSTRACT: Accurate software reliability evaluation requires the collection of comprehensive and consistent data sets on the ongoing software project. We define some measurements that can be performed on the software during its development or in operation to help evaluating and managing its reliability, and discuss organizational and feedback aspects. Since failure data are difficult to collect, the raw data set may include extraneous data: validation is thus needed before processing. Emphasis is put on near-term objectives, implying timely and efficient feedback for the ongoing project. However, as reliability measurement is to be considered in the first step in a software reliability improvement program, we report some success stories in which improvement programs have increased productivity and reliability at no extra cost or even with cost reduction
    Application-Specific Systems and Software Engineering and Technology, 1999. ASSET '99. Proceedings. 1999 IEEE Symposium on; 02/1999
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE To determine the effectiveness of the CT histogram method to characterize indeterminate adrenal nodules above 10 HU on noncontrast CT. METHOD AND MATERIALS Retrospective review of clinical CT data between January 2005 and December 2008 identified 198 indeterminate adrenal nodules (HU >10 on noncontrast CT) in 180 patients. 20 nodules in 18 patients were excluded due to large standard deviation (SD >30) of Hounsfield Unit values. Of the remaining 178 nodules, 133 were classified as lipid poor adrenal nodules based on size stability for ≥1 year (106), in- and opposed-phase MRI (17), adrenal protocol CT with contrast enhancement washout calculation (3), or biopsy (8). The remainder were classified as malignant by the following criteria: size increase over a short period of time (30), avid FDG uptake on PET/CT (17), or biopsy (5). Some nodules had more than one confirmation method. Histogram analysis was performed by drawing a circular region of interest (ROI) on all adrenal nodules. Mean attenuation, total number of pixels, number of negative pixels and percentage of negative pixels were recorded for each nodule. RESULTS With a threshold value of 15% negative pixels, there were no false benign judgments. 39 nodules had more than 15% negative pixels, all of which were benign adenomas (sensitivity 29%, specificity 100%, positive predictive value 100%). 29% of all adenomas >10 HU and 55% of adenomas between 11 and 20 HU contained ≥15% negative pixels. CONCLUSION The CT histogram method with a threshold value of 15% negative pixels can characterize many adrenal nodules with attenuation values >10 HU on noncontrast CT as adrenal adenomas, provided very “noisy” CT examinations (SD >30 HU) are eliminated. CLINICAL RELEVANCE/APPLICATION The CT histogram method can identify as benign a substantial percentage of adrenal nodules that would otherwise be classified as indeterminate by standard ROI analysis on noncontrast CT.
    Radiological Society of North America 2009 Scientific Assembly and Annual Meeting; 11/2009
Show more